Quantitative Investment Management LLC purchased a new stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 27,000 shares of the medical equipment provider’s stock, valued at approximately $3,258,000.
A number of other large investors have also recently bought and sold shares of the stock. Fred Alger Management Inc. bought a new stake in Zimmer Biomet during the 4th quarter valued at $4,209,000. Nomura Asset Management Co. Ltd. raised its holdings in Zimmer Biomet by 6.7% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 30,460 shares of the medical equipment provider’s stock valued at $3,675,000 after buying an additional 1,914 shares during the last quarter. Rock Springs Capital Management LP raised its holdings in Zimmer Biomet by 464.0% during the 4th quarter. Rock Springs Capital Management LP now owns 119,000 shares of the medical equipment provider’s stock valued at $14,360,000 after buying an additional 97,900 shares during the last quarter. University of Notre Dame DU Lac raised its holdings in Zimmer Biomet by 3.4% during the 4th quarter. University of Notre Dame DU Lac now owns 23,339 shares of the medical equipment provider’s stock valued at $2,816,000 after buying an additional 761 shares during the last quarter. Finally, Matrix Asset Advisors Inc. NY raised its holdings in Zimmer Biomet by 2.8% during the 4th quarter. Matrix Asset Advisors Inc. NY now owns 115,524 shares of the medical equipment provider’s stock valued at $13,940,000 after buying an additional 3,169 shares during the last quarter. Institutional investors own 86.64% of the company’s stock.
ZBH has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, November 20th. TheStreet lowered shares of Zimmer Biomet from a “b-” rating to a “c+” rating in a report on Friday, November 24th. BMO Capital Markets restated a “buy” rating and issued a $142.00 price objective on shares of Zimmer Biomet in a report on Tuesday, December 12th. Wells Fargo upgraded shares of Zimmer Biomet from a “market perform” rating to an “outperform” rating in a report on Tuesday, December 19th. Finally, Oppenheimer restated a “buy” rating on shares of Zimmer Biomet in a report on Tuesday, December 19th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $140.63.
Shares of Zimmer Biomet Holdings Inc (NYSE ZBH) opened at $116.83 on Friday. The firm has a market cap of $23,580.00, a PE ratio of 43.92, a PEG ratio of 2.02 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.50 and a quick ratio of 0.81. Zimmer Biomet Holdings Inc has a 1 year low of $108.03 and a 1 year high of $133.49.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $2.10. The firm had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.14 EPS. research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.8 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio is presently 36.09%.
In other Zimmer Biomet news, insider Bryan C. Hanson bought 25,077 shares of Zimmer Biomet stock in a transaction dated Tuesday, February 20th. The shares were purchased at an average cost of $119.68 per share, with a total value of $3,001,215.36. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Chad F. Phipps sold 20,826 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $115.95, for a total transaction of $2,414,774.70. The disclosure for this sale can be found here. 1.07% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Quantitative Investment Management LLC Purchases Shares of 27,000 Zimmer Biomet Holdings Inc (ZBH)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/17/quantitative-investment-management-llc-purchases-shares-of-27000-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.